Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
Is Now A Good Time To Buy BioMarin Stock?
07:55am, Friday, 22'nd Jan 2021
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
Top Wall Street analysts back these stocks as earnings season kicks off
07:53am, Sunday, 17'th Jan 2021
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Intel and BioMarin.
BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drug
10:59am, Monday, 11'th Jan 2021
Shares of BioMarin Pharmaceuticals Inc. tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3 clinical trial evaluating the experimental drug Roctavian a
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
09:47am, Monday, 11'th Jan 2021
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemoph
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene r
Primecap Curbs Holdings of Cree, BioMarin Pharmaceutical
12:21pm, Friday, 08'th Jan 2021
Firm also upped FibroGen stake in December
ALXN or BMRN: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 07'th Jan 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option?
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
08:00am, Monday, 04'th Jan 2021
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, pa
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets
12:38pm, Thursday, 24'th Dec 2020
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was ann
7 Undervalued Stocks That Could Soar in 2021
05:31am, Monday, 21'st Dec 2020
As markets flirt with record highs, there's more talk about overvalued stocks. However, it's time to consider undervalued stocks.
4 Biotechs That Could Be Potential Acquisition Targets in 2021
10:32am, Thursday, 17'th Dec 2020
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
10:00am, Thursday, 17'th Dec 2020
Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).
Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy
08:31am, Wednesday, 16'th Dec 2020
With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.
Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks
05:27pm, Friday, 11'th Dec 2020
Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96%
New York, New York--(Newsfile Corp. - November 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:
